Connect Biopharma(CNTB)
Focus: Connect Biopharma is a public immunology-focused pharmaceutical company headquartered in San Diego specializing in treatments for autoimmune diseases and inflammation. The company is in early-to-mid stage development with a public listing (CNTB) but generating modest near-term revenue.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
5+5 this month
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Should You Work at Connect Biopharma?
AI assessmentSuitable for risk-tolerant scientists and immunology specialists betting on CBP-201's Phase 3 success, but concerning cash burn and opaque pipeline warrant due diligence on runway and go/no-go decision timelines.
Why Work Here
- Focused immunology platform addressing large autoimmune disease markets with CBP-201 advancing to Phase 3 in atopic dermatitis
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$26M
Key Products
Peak
Multi-indication marketed asset in respiratory disease but appears to be a commodity medical air product with limited differentiation and no disclosed Part D spending.
Products & Portfolio (3)
Help build intelligence for Connect Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.